Contact Us
Drug Search Results
More Filters [+]

Lasofoxifene

Alternative Names: lasofoxifene
Latest Update: 2024-12-16
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ER Modulator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Vaginal

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: European Medicines Agency | Ireland | Portugal | Sweden

Approved Indications: None

Known Adverse Events: None

Company: Sermonix Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: Henlius Biotech

Clinical Description

Map of Global Clinical Trials for Lasofoxifene

Countries in Clinic: Australia, Belgium, Canada, China, Czech Republic, France, Germany, Hungary, Israel, Italy, Korea, Poland, Romania, Singapore, Spain, Taiwan, Turkey, United Kingdom, United States

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Breast Cancer

Phase 2: Dyspareunia|Multiple System Atrophy

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ELAINEIII

P3

Recruiting

Breast Cancer

2027-04-01

SMX 22-002

P3

Unknown Status

Breast Cancer

2026-10-30

ELAINEII

P2

Active, not recruiting

Breast Cancer

2024-12-31

SMX 18001

P2

Active, not recruiting

Breast Cancer

2024-12-01

57%

Recent News Events

Date

Type

Title

10/21/2024

News Article

 Sermonix Pharmaceuticals to Host Oral Presentation on Vaginal and Sexual Health at RISE UP for Breast Cancer Conference

10/01/2024

News Article

 Sermonix Pharmaceuticals' Lasofoxifene Demonstrates Anti-Estrogen Therapy Increases Immunotherapy Efficacy by Promoting Antitumor Activity of Eosinophils

08/27/2024

News Article

 Sermonix Pharmaceuticals Completes Enrollment of Phase 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer Setting

07/18/2024

News Article

 Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations

04/23/2024

PubMed

 Oral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trials.

11/19/2023

PubMed

 Novel Advances in the Role of Selective Estrogen Receptor Modulators in Hormonal Replacement Therapy: A Paradigm Shift.

09/01/2023

PubMed

 Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with Estrogen Receptor-Positive, Metastatic Breast Cancer with an ESR1 Mutation.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions